Call for the Fourth Quarter of Fiscal Year 2024. At this time, all participants have been placed in a listen-only mode and the call will be open for questions following management’s prepared remarks. During our Q&A session, please limit yourself to one question and one follow-up. I would now like to turn the call over to David Clair, Bio-Techne's Vice President of Investor Relations.

Good morning, and thank you for joining us. On the call with me this morning are Kim Kelderman, President and Chief Executive Officer; and Jim Hippel, Chief Financial Officer of Bio-Techne. Before we begin, let me briefly cover our safe harbor statement. Some of the comments made during this conference call may be considered forward-looking statements, including beliefs and expectations about the company’s future results. The company’s 10-K for fiscal year 2023 identifies certain factors that could cause the company’s actual results to differ materially from those projected in the forward-looking statements made during this call. The company does not undertake to update any forward-looking statements because of any new information or future events or developments. The 10-K, as well as the company’s other SEC filings, are available on the company’s website within its Investor Relations section. During the call, non-GAAP financial measures may be used to provide information pertinent to ongoing business performance. Tables reconciling these measures to the most comparable GAAP measures are available in the company’s press release issued earlier this morning on the Investor Relations section of the Bio-Techne Corporation website at www.bio-techne.com. Separately, in the coming weeks, we will be participating in the Morgan Stanley, Wells Fargo and Baird conferences. We look forward to connecting with many of you at these upcoming events. I will now turn the call over to Kim.

Thank you, Dave, and good morning, everyone. Thank you for joining us for our fourth quarter conference call. I’m pleased to report that our fourth quarter results came in line with our initial expectations. Continued stabilization of our end markets, combined with excellent execution by the Bio-Techne team, led to a 1% year-over-year organic revenue growth. This quarter wraps up our fiscal 2024, where our core portfolio of research and diagnostic reagents, together with the four growth verticals that leverage this content, delivered a 1% growth in what has proven to be a challenging fiscal year. It’s worth noting that these growth verticals have enabled Bio-Techne to consistently outperform our peer group during this unprecedented post-COVID pandemic period. During this period, we experienced a challenging funding environment for biotech and a significant R&D budget recalibration by large pharma and academia customers. Let me give you some examples of the business dynamics we’ve experienced throughout our fiscal year. First, our proteomics analytical franchise branded ProteinSimple. This business provides productivity tools for laboratories commonly used to expand laboratory capacity. However, these products are also well positioned for customers that are operating under constrained budgets and are looking to replace manual processes with simple and effective automation. Here, we saw mid-single-digit growth for the fiscal year, led by Simple Plex and Simple Western platforms, bolstered by double-digit growth for instrument-related consumables across all platforms. Our cell and gene therapy vertical, which is led by our quality GMP protein products, also grew mid-single digits for the year and added more customers even while biotech funding had a multiyear low. In our spatial biology vertical, we saw solid growth in fiscal year 2024 despite the budget reset by our pharma customers. Our new spatial biology instrument COMET is seeing robust adoption and will bring accelerated growth to this vertical in the years ahead. Lastly, the ongoing traction and market adoption of our ExoDx Prostate test, together with new product launches within our surging franchise, drove double-digit growth in our Molecular Diagnostics growth vertical all year long. It is these four growth verticals that have carried us through the challenging post-COVID dynamic market slowdown, and we are confident that these same verticals will drive accelerated growth as our core market and our core portfolio of 40 agents gradually recover back to long-term historical growth rates. Over the last 48 years, we’ve mapped the core portfolio of research reagents and diagnostic tools, which include a catalog of over 6,000 proteins and 400,000 antibody types. These products are critical components to many foundational workflows in virtually all life science academic and biopharma research labs globally. Not only do the reagents unlock the power of scientific discovery, they are also the synergistic force behind our four growth verticals. The five-year CAGR for these growth verticals is over 20%, and they accounted for about 45% of Bio-Techne’s revenue in fiscal 2024, which is significantly higher than the 30% of revenue in fiscal 2019. And that's only five years ago. Before we get into the details of the most recent quarter, I’d like to officially welcome Dr. Judith Klimovsky to Bio-Techne’s Board of Directors. Dr. Klimovsky is currently the Executive Vice President and Chief Development Officer at Genmab, and she brings a significant end-market, scientific and international experience to Bio-Techne’s Board. Dr. Klimovsky’s insight and guidance will be very beneficial as we continue to execute our strategy and expand globally. Welcome to our Board, Judith. Now let’s start with a discussion of our end markets and geographies, beginning with the biopharma end market, where we saw continued stabilization from our biopharma customers. Overall, biopharma declined low single digits in the quarter, but it was relatively consistent on a sequential basis. There is a broad awareness that biotech funding has been stronger for the first half of the calendar year, which is good news after a very challenging 2023. We anticipate that this recovery will bring incremental confidence to the capital-dependent companies and that this will eventually drive increased demand for our portfolio of life science products in the coming quarters. Academia decreased low single digits in the quarter, reflecting a particularly challenging comparison with the same period last year during which revenue increased upper single digits. From a geographic perspective, North America and Europe both declined low single digits in the quarter, reflecting the aforementioned constraints in biopharma and academic end markets. Although it is worth noting that Europe had particularly difficult comparables, as it had double-digit growth in the fourth quarter last year. For China, the stabilization trend that we have experienced over the past several quarters fortunately continued into Q4. As China progressed through a recovery process, we would expect our portfolio of research reagents to be among the first to return to growth, followed by our instrument portfolio. This prognosis is strengthened by the fact that our team in China delivered their second consecutive quarter of double-digit growth for our core reagent portfolio. This performance was paired with mid-single-digit growth in our biologics portfolio, which consists primarily of the Maurice family of instruments and associated consumables. Overall, China declined high single digits in the fourth quarter, which was in line with our expectations, as last year’s stimulus resulted in a comparison of mid-teens growth for this geography in last year's Q4. While the impact of the recently announced stimulus will likely not translate into revenue growth for the region until the second half of our fiscal year, we are encouraged by the overall stabilization in this region and the early return of the growth to our reagents. Let's discuss our growth pillars in more detail, starting with ProteinSimple instrumentation within the Protein Sciences segment, where overall organic growth was low single digit for the quarter. As mentioned, robust utilization of these productivity tools drove double-digit consumable growth. It's worth highlighting that our Q4 is the seventh consecutive quarter in which the consumables related to our instruments grew at least double digits, indicating strong utilization of our global installed base. Our protein analysis instrument provides automation, decision-making, reproducibility, and labor savings, which makes them increasingly ingrained in both academic and biopharma workflows. Our automated multiplexing immunoassay instrument named Ella was a standout performer within the ProteinSimple portfolio as both the instrument and related consumables increased double digits in the quarter. Ella is quickly becoming the go-to platform for cell and gene therapy customers for viral titer and release testing. Ella is also seeing rapid adoption among CROs looking for high reproducibility paired with high sensitivity in an easy-to-use, fully automated immunoassay platform. Related to immunoassay technology, we recently announced an investment in Spear Bio’s Series A funding plan. Spear Bio is an innovation leader in the development and manufacture of ultrasensitive immunoassays capable of measuring protein markers at automolar levels from sub-microliter sample volumes. Spear Bio’s assays run on qPCR equipment, which is routinely found in research and clinical facilities, tapping into a very broad existing installed base. Spear Bio’s initial assay will focus on key biomarkers supporting translational research in Alzheimer’s disease. Within our ProteinSimple franchise, we also recently announced the latest addition to our Simple Western platforms called Leo. As a reminder, our Simple Western platforms automate the manual, laborious, cumbersome, time-consuming, and inconsistent western blotting process commonly used to identify proteins in complex mixtures. Leo is the high throughput automated western blot system enabling the simultaneous analysis of up to 100 samples in a single three-hour run. We are excited to introduce this next-generation system, which is expected to begin shipping in the second half of our fiscal year 2025. We remain the only fully automated western blot technology provider on the market and see a long runway for future growth with this portfolio, as our current market penetration is below 30%. Like our other platforms, Simple Western continues to gain traction in cell and gene therapy applications as the system is increasingly used for absolute protein quantitation and relative potency assays. For example, Regulus Therapeutics recently reported positive top-line data from the second cohort of patients in its Phase 1b study related to the treatment of a kidney disease called ADPKD. Regulus utilized our Simple Western platform to develop high-performance biomarker assays to measure various proteins in urine as part of this study. We look forward to working with Regulus and, of course, with all our other partners to further the advancement of cell and gene therapy. I’ll now shift to the other growth pillars within our Protein Science segment, our cell and gene therapy business unit. This growth vertical includes a proteomic reagent and scalable workflow solutions that enable our customers to accelerate e-clinical, clinical, and eventually the commercialization of these next-generation therapeutics. As we’ve mentioned in the past, order timing from large customers can create quarter-to-quarter lumpiness in our GMP proteins business, and that was indeed the case in our Q4. As a sign of underlying strength, however, we are pleased to see continued growth in the number of customers utilizing our highly active GMP protein. We will continue to actively seed the market to ensure we partner with our customers early in their development journey. Within our GMP reagent offering, we continue to drive significant growth in our GMP small molecules business. These small molecules are key components in the reprogramming, self-renewal, storage, and differentiation processes critical to regenerative medicine workflows. We are making good progress with our new GMP facility in Bristol, UK, which positions us well to meet current and forecasted demand for those critical reagents. This small molecule business grew nearly 50% for the quarter and is quickly becoming a material contributor to our overall cell and gene therapy results. In total, our Protein Science segment declined 3% organically for the quarter and declined 2% for the fiscal year. Remember that our Protein Science segment has the most exposure to both China and the biopharma end market, and that this segment is positioned to see the most significant improvement as these end markets recover. Now, let’s discuss the growth pillars in our Diagnostics and Genomics segment where organic revenue grew by 9% in the quarter and 6% for the full fiscal year. Our molecular diagnostics growth pillar performed exceptionally well, as organic revenue growth topped 20%. The value proposition of our ExoDx Prostate test continues to resonate with both patients and physicians. It provides critical information to men with a gray zone PSA score on whether to proceed or not to proceed with an invasive and potentially dangerous prostate biopsy. During Q4, ExoDx Prostate volumes increased by almost 35%. We are seeing momentum across the various KPIs we track for our ExoDx Prostate test, including a 30% sequential increase in the number of physicians ordering 25 or more ExoDx Prostate tests per quarter. Rounding out our molecular diagnostics business, the Asuragen brand delivered another strong quarter as the sensitivity and specificity of our proprietary assay chemistry drive global adoption of our carrier screening as well as our oncology kit. This led to mid-teens overall growth for the business, and we continue to advance innovative molecular diagnostic products through our pipeline and are looking forward to the launch of our exosome-based ESR1 mutation kit for breast cancer monitoring as well as the expanded carrier screening essay in the coming months. Now let’s discuss our spatial biology growth pillar where, once again, demand for a fully automated high-throughput hyperplex spatial biology platform called Comet outpaced our manufacturing capacity in the quarter. The cross-organizational manufacturing team continues to implement production process improvements and is making good progress scaling capacity to meet current and forecasted Comet demand. During the quarter, we enabled RNA detection and visualization on Comet with the launch of RNAscope HiPlex capabilities for the instrument. Following this launch, Comet is now capable of detecting and visualizing up to 24 plate proteins and 12 RNA targets simultaneously, creating a highly differentiated multiomic system for the rapidly growing spatial biology market. These enhanced capabilities are in the hands of our initial set of key opinion leaders and will be rolling out across our installed base over the coming months. In summary, the team delivered another solid quarter and another solid fiscal year in this challenging funding environment. As our end markets equilibrate back to a non-pandemic environment, we are well positioned to reinvigorate growth across our portfolio of core research reagents and continue momentum across our four growth verticals. I’m extremely proud of the execution by the Bio-Techne team in the stabilizing but still challenging end market. I’m also confident in our ability to deliver differentiated financial performance as our end markets progress through the recovery process. With that, I’ll turn the call over to Jim.

Thanks, Kim. I’ll start with some additional detail on our Q4 and fiscal 2024 financial performance and then give some thoughts on the financial outlook for the year ahead. Starting with the overall fourth quarter financial performance. Adjusted EPS was $0.49 compared to $0.55 in the prior year quarter, with foreign exchange having an immaterial impact on EPS. GAAP EPS for the quarter was $0.25 compared to $0.47 in the prior year. Q4 revenue was $306.1 million, an increase of 2% year-over-year on a reported basis, a 1% increase on an organic basis. Acquisitions contributed 1% to reported growth. The full fiscal year 2024 revenue approached $1.2 billion and organic growth was comparable to what we saw in the fourth quarter. Looking at our organic growth by region and end market. In Q4, North America and Europe decreased low single digits year-over-year, while China decreased high single digits. APAC outside of China increased low double digits overall, with Japan and Australia both benefiting from growth in cell and gene therapy and the regional expansion of our Asuragen portfolio, respectively. While lower government funding and macro constraints continue to impact South Korea. By end market in Q4, excluding China, both biopharma and academia declined low single digits in the quarter. As Kim previously mentioned, we continue to see sequential global stability in our biopharma end market, while academia faced tougher year-over-year comps this quarter. Below revenue on the P&L, total company adjusted gross margin was 71.1% in the quarter compared to 71.6% in the same quarter the prior year, driven by the impact of the Lunaphore acquisition and unfavorable product mix, partially offset by productivity initiatives. Adjusted SG&A in Q4 was 29.8% of revenue compared to 26.8% in the prior year, while R&D expense in Q4 was 7.8% of revenue consistent with the prior year. The increase in SG&A was driven primarily by the Lunaphore acquisition as well as the quarterly timing of annual incentive compensation accruals. Adjusted operating margin for Q4 was 33.5%, a decrease of 360 basis points from the prior year period, but an increase of 50 basis points sequentially. Excluding the Lunaphore acquisition, which closed at the beginning of Q1, adjusted operating margin was 120 basis points lower than the prior year due to the impact of unfavorable volume leverage and product mix. Looking at our numbers below operating income, net interest expense in Q4 was $1.5 million, decreasing $1 million compared to the prior year period due to lower debt levels. Our bank debt on the balance sheet as of the end of Q4 stood at $319 million, a decrease of $70 million compared to last quarter. Other adjusted non-operating income was $0.5 million in the quarter, an increase of $0.6 million compared to the prior year, primarily reflecting our 20% share of Wilson Wolf’s adjusted net income, partially offset by the foreign exchange impact related to our cash pooling arrangements. Moving further down the P&L, our adjusted effective tax rate in Q4 was 22%, consistent throughout fiscal 2024, but up 200 basis points compared to the prior year due to geographic mix. Turning to cash flow and return of capital, $75.5 million of cash was generated from operations in the quarter, and our net investment in capital expenditures was $18 million. Also during Q4, we returned capital to shareholders by way of $12.6 million in dividends. We finished the quarter with 160.7 million average diluted shares outstanding. Our balance sheet finished Q4 in a strong position with $151.8 million in cash and our total leverage ratio remains well below 1x EBITDA. Going forward, M&A remains the top priority for capital allocation. Now let’s discuss the performance of our reporting segments, starting with the Protein Sciences segment. Q4 reported sales were $214 million, which reported revenue decreasing 4% compared to the prior year period. As discussed in last quarter’s call, on a strategic review of our portfolio, we have decided to divest the fetal bovine serum or FBS business. FBS is approximately a $10 million annual revenue business with an operating margin profile and long-term growth rate below the company average. The exclusion of FBS unfavorably impacted reported segment revenue growth by 1%. Thus, organic revenue for the segment decreased 3%. As a reminder, it is our Protein Sciences segment that has the most exposure to the China geographic region as well as to the biotech end market. Operating margin for the Protein Sciences segment was 43%, a decrease of 170 basis points compared to the prior year quarter as unfavorable volume and product mix were partially offset by cost management and structural alignment initiatives. Now turning to the Diagnostics and Genomics segment, Q4 sales were $90.7 million, with reported growth increasing 15% compared to the same quarter last year. Organic revenue growth for the segment was 9% with the Lunaphore acquisition having a 6% impact. Lunaphore diagnostics growth vertical once again led segment growth. Moving on to the Diagnostics and Genomics segment operating margin at 12.5%. The segment’s operating margin decreased compared to the prior year’s 18.5%, due primarily to the impact of the Lunaphore acquisition. Excluding Lunaphore, the segment’s operating margin would have been over 20%. Diagnostics and Genomics steadily improved operating margins throughout fiscal 2024, benefiting from the integration of Lunaphore and sequentially increasing volume leverage. The segment’s operating margin improved 320 basis points sequentially from Q3 and improved from nearly breakeven operating margin at the beginning of the year in Q1. In summary, as we reflect on this past fiscal year, it has really been a multiyear unwinding of a massive investment that occurred in our industry and end markets during the COVID pandemic. We are pleased that our strategic portfolio positioning, together with resilient execution by our 3,100 employees, has enabled Bio-Techne’s annual revenue to be higher today than it was before the unwinding began. We are encouraged that the past two quarters of sequential stabilization in our end markets suggest that the unwinding is largely behind us. Now, our industry waits for a return to normalized market growth, which we believe, in life sciences, is mid-single-digit growth over the long term. How long will it take for this recovery to happen is a challenge for anyone to predict. But there are indications that a gradual recovery in the back half of calendar year 2024 and throughout calendar 2025 is a real possibility. These indications include the following: OEM customer destocking appears to have abated. Biotech funding in the first half of calendar year 2024 has improved significantly from 2023 levels. Large pharma customers may have completed the realignment of their R&D pipeline priorities by the end of calendar 2024, with the pandemic now in the rearview mirror and the implications of new pharma industry-specific government regulation better understood. Finally, the China region should realize a lift in instrument growth at the start of calendar 2025 due to announced government stimulus. As our end markets gradually recover, we believe that biotech needs relative revenue growth. Outperformance will also continue. The value proposition at our proteomic analysis platforms has demonstrated to our customers during this downturn and has resonated in strong instrument-based consumable growth over the past two years. By our calculation, there is pent-up demand and a need for more instruments. Our cell and gene therapy offerings have demonstrated value propositions by adding new customers throughout the past two years, even when new biotech funding has been drastically reduced. Our spatial biology growth vertical now has an automated solution unmatched in its speed and multiomic capabilities that will also pull through larger quantities of our gold standard RNA scope and antibody reagents. Last but not least, our Molecular Diagnostics growth vertical is already in growth acceleration mode as its unique and underpenetrated portfolio of products continues to take market share. Thus, the gradual road to end market recovery over the next 18 months, together with our expectation for continued outperformance forms our baseline case for Bio-Techne’s organic revenue growth in fiscal 2025. Our current momentum suggests low single-digit growth in the first half of the year with a possibility of mid-single-digit growth once the higher biotech funding returns into biotech spending. Our organic growth will gradually accelerate to the high single digits in the second half of the year as Chinese stimulus funds are released and assuming large pharma budgets are normalized for the calendar year 2025. As we look to adjusted operating margins for the year ahead, we intend to fund all new investments with productivity initiatives and cover inflation with pricing actions, allowing anticipated volume leverage to drop through to the bottom line. However, following a year of missed incentive compensation targets, there will need to be a reinstatement of incentive compensation accruals for both bonuses and sales commissions. The impact of this reinstatement will create an approximately 100 basis point headwind to fiscal year 2025's full-year adjusted operating margin and will more severely impact the first half of the year than the back half. Thus, we expect the first half adjusted operating margin for fiscal year 2025 to be approximately 200 to 300 basis points lower than the prior year and the second half margin to be approximately 100 to 200 basis points higher than the prior year. The first half of the year will have margin headwinds related to the incentive compensation reinstatement as well as continued negative product mix, while the second half margin should benefit from greater revenue volume leverage, planned productivity initiatives, and improving product mix. Assuming the indicators that we are all seeing are correct, fiscal year 2025 should be the year of gradual recovery for our end markets, which will allow us to exit the year poised for double-digit growth in a multiyear run towards adjusted operating margins of 35% as per our long-term objectives. That concludes my prepared comments. And with that, I’ll turn the call back over to the operator to open the line for questions.

We’ll take our first question from Puneet Souda with Leerink Partners. Your line is open.

Hi, guys. Thanks for taking my questions. I’m just wondering if you can elaborate a bit on the RUO antibodies and cytokines in the quarter. How did that fare? And also, it seems that your instrumentation portfolio is still holding up while your attached consumables are growing with that instrumentation portfolio. Maybe just help us understand the instrumentation dynamic a bit because when we look at the peers, the instrumentation has been weaker, but it just seems like there is a bit more demand. Maybe part of that is Lunaphore. Just if you could help clarify the instrumentation as well on that end.

Puneet, good morning. Thanks for your question. Let me start with the instrument question that you asked. Yes, like most others, our instrumentation growth rates have been under pressure in the end markets, as we know them, specifically China and biopharma being constrained. But we’re also proud to mention that the consumables directly related to these instruments have been growing double digits now for seven quarters in a row. So we are very confident that the installed base is getting utilized optimally and that we are filling up capacity that we have in the installed base. With funding coming back in, we are pretty certain that there will be a drive to get increased capacity in the field, which will drive our instrumentation numbers. Your question on the RUO antibodies, there have been dynamics with the different end markets swinging a little bit in a bottoming out process, and that makes it a lumpy business. Overall, we are looking carefully at all the different product lines. We see some lumpiness quarter-over-quarter, but nothing that we are concerned about. Overall, we feel that portfolio is nicely positioned.

Okay. Thanks. And then, Jim, just clarifying the comments on fiscal year 2025. Does this mean a mid- to high-single digit overall for 2025 and an exit rate in the fourth quarter of 2025 of low double digits? Just wanted to make sure I was clear on that for organic growth.

Well, I guess, as I said, I’ve given some guidance on how I think the year will progress based on a baseline market expectation. That baseline market expectation is for a very gradual improvement in our end markets. I don’t think we see anything immediately that would suggest an improvement in our end markets in the very near term. But by the end of the year, we’re hoping that we start to see some uplift in biotech, given the increased funding that we’ve seen so far year-to-date that should turn to spending. In addition, by 2025, you have Chinese stimulus starting to kick in and pharma budgets being reset. So that’s kind of a gradual progression of the growth rates as we see it. That is what I’ve outlined in my prepared comments. And how fast that progression happens or how slow it happens will depend on what the full-year number ends up being.

Our next question comes from Jacob Johnson with Stephens. Your line is open.

Hey, thanks. Good morning. Maybe Jim, sticking on the guidance theme, I heard some headwinds on the margin side in the first half of the year due to incentive compensation, et cetera. It sounds like maybe a little bit better in the back half of the year, but still we’re looking at operating margins in FY 2024 that are well below where you’ve been historically. I know some of that is related to acquisitions. I guess as we think about returning to growth in the back part of this year, how should we think about incremental margins as growth picks up again? And then I heard 35% plus. But at times, we’ve seen a 40% target longer term. Is there any reason you couldn’t get back to 40% over time with the caveat of M&A possibly being dilutive to margins?

Yes. Thanks for the question, Jacob. Just to reiterate, from a margin perspective, we do have a significant headwind with the incentive compensation accrual restatements across the entire company. It’s about 100 basis points. So without that headwind, we would be talking about some incremental margin improvement this year. That being said, we do see a line of sight assuming the growth rates accelerate throughout the year. We do see line of sight to adjusted operating margins being 100 basis points to 200 basis points higher than we ended this year, which would get us somewhere in the mid-30s. My comment around 35% was actually greater than 35%, so it was really the message that we see this year as a year of recovery that would set us up nicely to get back to our long-term growth objectives, which is north of 35% operating margin, up to 40%, of course. That’s the range we’ve always stated, and we expect to be back on track to our long-term growth plan. So that was the main message behind that comment.

Got it. Makes sense. Thanks for that, Jim. And then, Kim, maybe Jim mentioned getting back to double-digit growth. Maybe just to revisit the 2023 Investor Day and the potential for growth well into the double digits. You talked about your four key growth franchises earlier and the traction there. And obviously, those are key to more robust levels of growth when the macro normalizes. I’m just curious, a year later after that Investor Day, are there any of those four platforms where you’re more confident in the growth outlook? And then on the flip side, any of those pillars where maybe you have more restrained expectations?

Thank you, Jacob. It’s a good question. It is quite comforting that we look at these four growth verticals very carefully because those are also areas where investment dollars flow in, and our activity level is very high. We continuously look at our programs there, but also the competitive landscape. And you take that all together, and we’re still very committed to each and every one of those. We’ve seen improvement in our differentiated position with a wonderful symbiosis between those four growth verticals and the core reagents, where each of these growth verticals pulls through. Our core reagents have very high margins, and we have very differentiated positions in the market. So we’re still very confident about it. The difference you would ask is, what is the difference between now and a year and a half ago? The difference is that the end markets have slowed since, and the question is not so much, will we get to the numbers projected at that time, but rather when will we get to those numbers? That timeframe is slightly delayed. In a five-year forecast, you always think about a couple of mediocre years, a couple of good years, and a couple of bad years. Unfortunately, now we’ve had a couple of lackluster years behind us. Hopefully, those are the last ones, and we’re still on track. It could well be that it takes a little longer, and we would have to think about delaying the $2 billion mark. But whether we get there is not the question, and we’re really confident with our platforms.

Our next question comes from Dan Arias with Stifel. Your line is open.

Hey, good morning, guys. Thanks for the questions here. Jim, just looking at the model, can you maybe true us up on where GMP reagent revenue finished for the year? And then what you think a good starting point on growth might be for this year, new products, I believe, but still recovering customer spending. So what do you think that translates to for 2025, just given the importance there to the growth algorithm?

Yes. Thanks for the question, Dan. GMP overall GMP revenue growth for fiscal year 2024 did grow. We were did have growth overall for the year, even though it was choppy, which is a positive sign in a very tough year. Thus, we expect those growth rates to increase with an improving market. That’s essentially what has been baked into the forward guidance.

Okay. But is there any way you can kind of like give us a number to work with as a jumping-off point?

Well, I’d say this, we grew roughly mid-single digits for the full year in 2024.

Okay. And then maybe just as a follow-up on the outlook and the growth that the company is capable of here. One of the things that you usually talk about when it comes to forecasting is this idea that Bio-Techne has historically and consistently been 500 basis points to 1,000 basis points above peers on organic growth. To what extent do you think that logic applies in 2025, if we just think about the assumptions on market growth that are implied there?

I mean, we’re sticking with that guidance, right? This quarter is yet another testament to it. Our peer group in total shrank roughly about 4% this quarter, and we grew 1%. Getting back to Puneet’s question about getting back to double-digit growth, we are absolutely confident that when the market gets back to mid-single-digit growth, we will be at double digits. Predicting when that full market recovery happens is difficult to do. But we’re trying to convey that a slower pace is expected for recovery. That calendar year 2025 will be a year of recovery, and it might take that full calendar year to get there, which is why we’re being a bit conservative on the fiscal basis ending in June. We’ve heard from our peers that bio production is looking to recover perhaps a bit sooner, which might be the first jolt the industry needs. There are several positive signs, and we call them green shoots last quarter. I think they are still green shoots this quarter; they just haven’t quite sprouted yet. We also have company-specific activity that will help our growth rate, such as Lunaphore, the Comet launch, which gives us multiomic capabilities, creating additional upside for growth.

Next question is from Dan Leonard with UBS. Your line is open.

Thank you. I have a question on your RUO reagent product line. Is there anything you could do to accelerate growth there independent of market improvement?

Yes. Thanks for the question. The linkage to the growth platform is key there. Some of the RUO reagents fit nicely in pull-through. As you know, we are now enabling the Comet instruments to utilize our Bio-Techne antibodies that sit in the RUO reagents. These mechanisms will start pulling through the core. Of course, the core goes to market itself, but that is the lackluster end market. Now we can also think about how to better get through that than others by continuing to improve and solidify our marketplace as well. So the marketplace, making sure that it's easy to transact with Bio-Techne and that our website is in great shape, combined with the vertical platforms pushing through those reagents, is the secret sauce there. Fortunately, in parts of the portfolio that is already working, because some of the RUO product lines are already in the black. Thanks for the question.

Got it. Appreciate that. And Kim, correct me if I'm wrong, but it seems like your spatial portfolio is less subject to macro headwinds. So could you size that portfolio in aggregate at this point? And how fast do you think it grows in 2025?

Yes. Fortunately, we've seen some resilience in that portfolio. But I wouldn't say it's immune, right. There are still larger pharma customers that would have a run rate of $1 million or more in quarterly usage of some of our reagents. There is shuffling going on in an end market in which sometimes the programs get closed, or sometimes locations get consolidated. Now overall, I don't think that will have a long-term effect on the need for spatial biology. I'm very confident that we'll be there. However, the shuffling in the interim could result in some lumpiness. Overall, the run rate of that business is now at $120 million. We expect double-digit growth in the coming years, especially since we’re nicely combining a top-notch instrument in the market with the potential to pull through our RNA scope reagents as well as our antibodies. Right now, that instrument is running at just below 50,000 a quarter. Once we have all our reagents linked to it, we feel that pull-through could double, making it our highest pull-through instruments. I’m very confident this will be a very positive product line for us and will positively impact our company.

Our next question comes from Tom DeBourcy with Nephron Research. Your line is open.

Hi, thanks. This is Jack Meehan on for Tom. I was wondering if you could elaborate on what you're seeing as it relates to China stimulus, how that – what parts of the portfolio are exposed to that? And maybe just how it impacted the current quarter and confidence that steps up in the second half of the fiscal year?

Yes. Thanks, Jack. The funding program is trickling through the different systems and regional governments. It's certainly on its way, as we hear. Customers are certainly interested in receiving the benefits and are keen to spend the money already. It’s tailored primarily to instrumentation. I think we’re uniquely positioned to benefit from it. A couple of data points: first, our instrumentation creates efficiencies and improves the data obtained, which creates a fantastic value proposition. Secondly, about a year ago, a similar funding concept was put in place, and we truly benefited from it. That’s why our current Q4, the one we’re reporting on now, had relatively high comparables year-over-year due to that funding. This program is set for three years, so we feel that once these funds become available, we will benefit short-term. It should be a positive driver for the coming years ahead, which is, of course, better than just one quick jolt that then falls flat again. I’m optimistic about this concept. Our Ella product line and that one has already been growing very nicely in China. As I mentioned at the beginning of the earnings call, we have seen the consumables across all four of our platforms continue to grow double digits in the market, indicating healthy usage. Overall, I feel confident that this will be a positive driver for the company. However, like everyone else, the timing and when it trickles through is more vague, but I’m pretty certain that it's going to happen.

Our next question comes from Matt Larew with William Blair. Your line is open.

Hi, good morning. I wanted to start on Lunaphore. Obviously, for a few quarters now, you reported that demand is outstripping capacity. I know you brought manufacturing in-house and are attempting to scale that up. So could you just maybe speak to where you're at from a manufacturing perspective, related to the backlog? And how those two statements filter into what you think you can deliver from Lunaphore in fiscal 2025?

Yes. Thank you for the question. First of all, we are delighted that we saw healthy demand above our capacity, which is always a good starting point, albeit painful. Our teams have worked hard in cranking up capacity. Yes, we've been doing this for a little over two quarters. I’m very pleased to report progress. We mentioned that this was still a consideration in Q4, but in Q1 of fiscal year 2025, this problem should be resolved. The lines of capacity and demand are expected to cross any week or month now, and from there, we should not be held back by the capacity constraints anymore, allowing us to focus on increasing demand. So it’s looking very promising from that perspective. You might not hear about that topic anymore.

Okay. That’s good to hear. And then, Jim, just thinking about margins next year. Obviously, you gave the first half and second half guidance. But I think just kind of do a quick math on the top line and what it implies for margins that spending next year could lead to quite a bit less year-over-year growth than in recent years. You referenced some productivity programs. So maybe I just want to get a sense for where you're targeting from an efficiency perspective and kind of what the balance is between pulling costs out to get margins back in line, versus allocating investment for some of the future growth opportunities?

Yes. The reality is that we've been working on productivity initiatives throughout this down cycle, which flows into fiscal 2023, 2024 and will continue with more projects in fiscal year 2025 as well. It's a delicate balance between adjusting the structure inside our business relative to our volumes while maintaining and fueling the growth pillars, which allow us to outperform our competition and propel us to double-digit growth once the market returns to normal growth rates. We have been pretty successful in the initiatives we are doing and have line of sight to continue this year and basically offset any new investments we are making in growth pillars to keep moving forward with our five-year plan objectives. So it's an ongoing process for our company.

Our next question comes from Patrick Donnelly with Citi. Your line is open.

Hey guys, thanks for the questions. Maybe first, just on the outlook for the first half of low single digit organic growth, does that hold for the first quarter as well? And then any color on how we should think about protein sciences specifically in the first half versus the back half.

Yes, I’ll take that. Thank you, Catherine. Again, it’s a gradual, it’s a very gradual increase that we’re discussing fueled by market projections. I mentioned in my opening comments that we expect low to mid-single-digit growth in the first half, which would suggest some level of progression in both our end markets and our absolute performance. The improvement will largely come from our protein science segment, which has been most severely impacted by China, biotech funding issues, and the slowdown in big pharma. As those end markets recover, our Protein Sciences segment will recover the fastest and the most, improving our mix over time and margins throughout the year, which is another basis for believing the second half margins will be significantly better than the first half.

Our next question comes from Justin Bowers with Deutsche Bank. Your line is open.

Can you talk about the biopharma end market and how that performed across the different geographies? And then any notable pockets of outperformance or underperformance across the different growth pillars?

Yes, biopharma taking China out of the mix, we report biopharma excluding China, which was basically low single-digit growth and was very consistent globally, both in Europe and the U.S., again showing low single-digit decline. More importantly, the sequential performance of biopharma was consistent in Q4 as it was in Q3. While growth rates can be erratic, it’s crucial to focus on the momentum of the business going forward since 80% of our business is consumables that book and ship the same day. The overall momentum, even within biopharma, has at least stabilized. We’ve been indicating that the December quarter felt like a bit of a bottom, and we’re in a bottoming process until the markets start to fully recover. There are reasons to believe from a macro perspective that recovery will be sooner than later, but it will likely be a gradual process moving forward.

Thanks, Jim. A quick follow-up on Lunaphore. Is the linking of the reagents to the instruments a multi-quarter or multi-year process? Can you talk about that and the phasing a little bit?

Yes. The initiation of linking the RNAscope HiPlex to the box is happening this quarter and will roll out throughout this quarter. The antibodies can be used right now, so they are already in place. Will we broaden that portfolio and add different tools to it? Yes, but that will be a filling-out process over the coming quarters and years. However, to start doing your experiments across most diseases and fully automated multiomics is possible within the coming months.

We’ll take our final question from Sung Ji Nam with Scotiabank. Your line is open.

Hi. Thanks for taking my questions. Just on the academic end market. I know it’s relatively small. But is the expectation there also for that segment to gradually recover throughout fiscal year 2025, given comps get easier? Could you highlight some of the key puts and takes for that end market?

Yes. From an academic perspective, it has been a dynamic environment, both during and post-pandemic. Tracking our peers’ performances, we've generally seen low single-digit to mid-single-digit growth in our space. We encountered some lumpiness in our comps this quarter, but we are predicting low single-digit market growth in academia going forward. It has been consistent over the years, with much of the NIH funding, as well as the Horizon funding in Europe, focusing now on infectious diseases and related technologies initiated due to the pandemic. A normalization toward studies and sciences around neurology and immuno-oncology, areas we are strong in, is a positive driver.

I think there are fundamental improvements where we are taking share as well. There are certainly dynamics at play that we won’t always count on for future growth, as we experienced a few quarters of inventory adjustments. We noted that with the destocking pattern, we were going through a couple of quarters resulting in lackluster performance. That has ended, and we believe it will benefit us going forward. However, I do believe there’s underlying strength still, and we are taking market share.

It appears we have no further questions. I’ll turn the program back to the speakers for any additional or closing remarks.

Yes, I will go ahead with closing statements. Thank you very much for joining the call today and for all the insightful questions. I’m extremely proud of the Bio-Techne team’s accomplishments and all the results that we have been able to deliver in the quarter and in the fiscal year even under the current market conditions. Our differentiated portfolio addresses some of the highest growth markets in life sciences and is positioned to deliver best-in-class performance for all of our stakeholders going forward. So thank you very much and to the next earnings call.

This does conclude today’s program. Thank you for your participation, and you may disconnect your lines at any time.